John F. Burd, J Obes Weight Loss Ther 2019, Volume 9
DOI: 10.4172/2165-7904-C1-090

Glucose toxicity: The worldwide problem and the all-natural solution

John F. Burd
Lysulin, Inc., USA

Glucose toxicity is an epidemic problem leading to the insulin resistance and the development of obesity, pre-diabetes and Type 2 diabetes in both children and adults. In addition to poor health and early death, this is costing our healthcare systems a fortune to treat diabetes and its complications. Glucose is not a passive bystander in our bloodstream but is a toxic and reactive compound. Glucose reacts with all of the proteins in our body forming Glycated Proteins. These glycated proteins progress to become what is known as Advanced Glycation End-products Advanced Glycation End-products or AGEs. These AGEs are known to be the culprits in the disease complications associated with diabetes including kidney failure, blindness, amputations and cardiovascular disease. Protein glycation is also be the cause of insulin resistance. Insulin resistance not only leads to high blood glucose levels in our bloodstream, but also leads to insulin depletion. When this happens, we may have to resort to injection of insulin in an attempt to keep our blood glucose levels in the normal range. There is now an all-natural solution to the glucose toxicity problem. In over 20 years of R&D and clinical studies, nutritional supplements have been proven to combat glucose toxicity. Three important supplements having this ability are the Lysine, zinc and vitamin C. Combining these three important supplements into one tablet makes a powerful weapon to combat glucose toxicity and protein glycation. This weapon is Lysulin®. Unlike the available prescription drugs for type 2 diabetes which are directed at the symptoms of diabetes (high blood glucose), Lysulin is the first product directed at the problem, which is glucose toxicity and protein glycation. Clinical studies have proven that Lysulin lowers HbA1c better than the vast majority of prescription drugs. Current therapy for type 2 diabetes and the history of studies proving the effectiveness of Lysulin will be presented along with recent data from double blind placebo controlled studies with Lysulin.

Biography

John F. Burd is Founder & CEO of Lysulin, Inc, and has launched an all-natural, scientifically proven nutraceutical product proven to improve the health of people with diabetes. He was also the cofounder of Sabur Technology, Inc., developing a new non-invasive continuous glucose monitoring technology. Prior to Sabur, He was a General Partner of Windamere Venture Partners. He was previously President & CEO of DexCom, now the leader in continuing glucose monitoring for people with diabetes. He has authored over 40 publications and holds 35 patents. He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin. In 2010, he was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.

jburd@jburd.com

Notes: